210 related articles for article (PubMed ID: 32766590)
1. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
bioRxiv; 2020 Jul; ():. PubMed ID: 32766590
[TBL] [Abstract][Full Text] [Related]
2. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33158912
[TBL] [Abstract][Full Text] [Related]
3. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
[TBL] [Abstract][Full Text] [Related]
4. The S1'-S3' Pocket of the SARS-CoV-2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors.
Liu M; Li J; Liu W; Yang Y; Zhang M; Ye Y; Zhu W; Zhou C; Zhai H; Xu Z; Zhang G; Huang H
Angew Chem Int Ed Engl; 2023 Oct; 62(41):e202309657. PubMed ID: 37609788
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
bioRxiv; 2020 Jan; ():. PubMed ID: 32511378
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
7. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
[TBL] [Abstract][Full Text] [Related]
9. The
Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Blankenship L; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
bioRxiv; 2021 Dec; ():. PubMed ID: 34981058
[TBL] [Abstract][Full Text] [Related]
10. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
Xia Z; Sacco M; Hu Y; Ma C; Meng X; Zhang F; Szeto T; Xiang Y; Chen Y; Wang J
ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1408-1421. PubMed ID: 34414360
[TBL] [Abstract][Full Text] [Related]
11. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
bioRxiv; 2020 Nov; ():. PubMed ID: 33140049
[TBL] [Abstract][Full Text] [Related]
12. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
Tan B; Joyce R; Tan H; Hu Y; Wang J
Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
[TBL] [Abstract][Full Text] [Related]
14. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on the design and discovery of α-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?
Nocentini A; Capasso C; Supuran CT
Expert Opin Drug Discov; 2022 Jun; 17(6):547-557. PubMed ID: 35282759
[TBL] [Abstract][Full Text] [Related]
16. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
17. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
Zeng Q; Antia A; Casorla-Perez LA; Puray-Chavez M; Kutluay SB; Ciorba MA; Ding S
mBio; 2024 Mar; 15(3):e0228723. PubMed ID: 38349185
[TBL] [Abstract][Full Text] [Related]
18. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
[TBL] [Abstract][Full Text] [Related]
19. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
[TBL] [Abstract][Full Text] [Related]
20. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
